P138: Management of aromatase inhibitor associated bone loss in post-menopausal breast cancer patients: A re-audit of bone health standards following introduction of a dedicated osteoporosis service

Publication date: June 2020Source: European Journal of Surgical Oncology, Volume 46, Issue 6Author(s): Ashleigh Bell, Sheena Waters, Yousif Shanshal, Robert Milligan
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research

Related Links:

We present a narrative review of the benefits versus risks of using MHT in the management of postmenopausal osteoporosis. Current literature suggests robust anti-fracture efficacy of MHT in patients unselected for low BMD, regardless of concomitant use with progestogens, but with limited evidence of persisting skeletal benefits following cessation of therapy. Side effects include cardiovascular events, thromboembolic disease, stroke and breast cancer, but the benefit-risk profile differs according to the use of opposed versus unopposed oestrogens, type of oestrogen/progestogen, dose and route of delivery and, for cardiovas...
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
ConclusionsEpidemiological evidence is rather consistent suggesting that there is a positive association between HRT use and MD with the highest increase in MD among current users, and CEP users. Our results suggest that due to increase in MD and masking effect, current E  + P users may require additional screening procedures, shorter screening intervals, or using advanced imaging techniques.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Often we don’t really consider gender dynamics in treatment or medication. A lot of medications are only tested on men because of the risk of pregnancy, etc. This means there are whole drugs that have made it to market that may not have ever been tested with women. Schizophrenia affects women in many different ways than men. In this episode schizophrenic Rachel Star Withers and cohost Gabe Howard discuss differences in age, symptoms, treatments, lifestyle, parenthood in the genders as they experience schizophrenia. Dr. Hayden Finch joins to explain the medical side.  Highlights in “Schizophrenia in Women...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Inside Schizophrenia Mental Health and Wellness Women's Issues Gender Differences Mental Disorder Mental Illness Psychiatry Psychology Psychotherapy Women's Health women's mental health Source Type: blogs
In conclusion, this study suggests that epigenetic age acceleration is significantly associated with lung function in women older than 50 years. We hypothesised that this could be due to menopause. However, we have observed that menopause has minimal effect and therefore there is possibility of other unknown physiological factors at older age in females mediating the epigenetic age acceleration effect on lung function. While, it is still unknown what exactly epigenetic aging from DNA methylation measures, this study suggests it can be utilised as one of the important factors to assess women's lung health in old age. DNA me...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSIONS: Hormone replacement therapy may slightly improve overall survival in women who have undergone surgical treatment for EOC, but the certainty of the evidence is low. HRT may make little or no difference to quality of life, incidence of breast cancer, TIA, CVA and MI as the certainty of the evidence has been assessed as very low. There may be little or no effect of HRT use on progression-free survival. The evidence in this review is limited by imprecision and incompleteness of reported relevant outcomes and therefore the results should be interpreted with caution. Future well-designed RCTs are required as this is...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Undergoing earlier menopause is a sign of a greater burden of age-related damage and dysfunction, so it should not be surprising to see that this correlates with a greater incidence of chronic disease in the years thereafter. People with a greater burden of cell and tissue damage tend to exhibit all of the manifestations of aging earlier than their less damaged peers. These variations in damage burden and consequences from individual to individual are near all the results of lifestyle choices, particularly smoking, weight, and exercise, and environmental factors such as exposure to chronic viral infection. Genetics plays o...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
The objective is to provide a sound pathophysiological background along with evidence-based and practical recommendations for physicians managing such women. PMID: 31853818 [PubMed - as supplied by publisher]
Source: Hormones - Category: Endocrinology Tags: Hormones (Athens) Source Type: research
By HANS DUVEFELT, MD Medical researchers and their groupies – early adopters, thoughtleaders, those easily influenced or whatever you want to call them – never seem to learn that when you try to outsmart Mother Nature or Our Heavenly Father, whichever appeals more to your world view, you usually get your hand slapped. When I was a resident (1981-1984), I got penalized if I didn’t offer postmenopausal women estrogen-progesterone replacement therapy because it seemed obvious that if women with endogenous estrogen didn’t get many strokes or heart attacks and women without estrogen did, all we nee...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Medical Practice Physicians Primary Care Hans Duvefelt Source Type: blogs
AbstractPurpose of ReviewThe goal of the review is to assess the appropriateness of menopausal hormone therapy (MHT) for the primary prevention of bone loss in women at elevated risk in the early years after menopause.Recent FindingsEstrogen alone or combined with progestin to protect the uterus from cancer significantly reduces the risk of osteoporosis-related fractures. MHT increases type 1 collagen production and osteoblast survival and maintains the equilibrium between bone resorption and bone formation by modulating osteoblast/osteocyte and T cell regulation of osteoclasts. Estrogens have positive effects on muscle an...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
Rossana C. Zepeda Plant-derived compounds have recently attracted greater interest in the field of new therapeutic agent development. These compounds have been widely screened for their pharmacological effects. Polyphenols, such as soy-derived isoflavones, also called phytoestrogens, have been extensively studied due to their ability to inhibit carcinogenesis. These compounds are chemically similar to 17β-estradiol, and mimic the binding of estrogens to its receptors, exerting estrogenic effects in target organs. Genistein is an isoflavone derived from soy-rich products and accounts for about 60% of total isof...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Men | Menopause | Orthopaedics | Osteoporosis | Surgery